New combo therapy aims to boost lymphoma remission
NCT ID NCT07385989
First seen Feb 04, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This phase 2 trial tests whether adding golidocitinib to standard chemotherapy and an immunotherapy drug improves outcomes for people with advanced NK/T-cell lymphoma. About 40 adults with newly diagnosed stage III-IV or non-nasal disease will be randomly assigned to receive either the triple combo or standard treatment alone. The main goal is to see if more patients achieve complete remission after six cycles of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.